Personalized treatment of extensive stage small cell lung cancer: A case report and literature review
A 50-year-old female patient presented with post-exercise dyspnea in September 2016, and was subsequently diagnosed with SCLC with multiple brain and spinal metastases. The first-line treatment was etoposide combined with cisplatin and synchronously performed radiotherapy for the brain and spinal co...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.956372/full |
| _version_ | 1811309069974110208 |
|---|---|
| author | Huaiyu Wang Xuning Wang Suxin Jiang Jingna Zhu Jie Liu Chuanhong Zhou Yanjun Zhu Yong Han |
| author_facet | Huaiyu Wang Xuning Wang Suxin Jiang Jingna Zhu Jie Liu Chuanhong Zhou Yanjun Zhu Yong Han |
| author_sort | Huaiyu Wang |
| collection | DOAJ |
| description | A 50-year-old female patient presented with post-exercise dyspnea in September 2016, and was subsequently diagnosed with SCLC with multiple brain and spinal metastases. The first-line treatment was etoposide combined with cisplatin and synchronously performed radiotherapy for the brain and spinal cord metastases. She was treated with anlotinib after disease progression in December 2018 and continued to have clinical benefit for nearly 25 months. Unexpectedly, the patient can still benefit from further combination treatment with durvalumab after another disease progression in February 2021. Thus, it may be a potential option to use anlotinib along with immunotherapy after the anlotinib resistance in SCLC, but more clinical data are still needed to confirm it. Moreover, ctDNA dynamic monitoring was performed and reflected the outcome of the process of treatment. |
| first_indexed | 2024-04-13T09:35:09Z |
| format | Article |
| id | doaj.art-af32ddad96f84e79869acf5220a2683f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T09:35:09Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-af32ddad96f84e79869acf5220a2683f2022-12-22T02:52:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.956372956372Personalized treatment of extensive stage small cell lung cancer: A case report and literature reviewHuaiyu WangXuning WangSuxin JiangJingna ZhuJie LiuChuanhong ZhouYanjun ZhuYong HanA 50-year-old female patient presented with post-exercise dyspnea in September 2016, and was subsequently diagnosed with SCLC with multiple brain and spinal metastases. The first-line treatment was etoposide combined with cisplatin and synchronously performed radiotherapy for the brain and spinal cord metastases. She was treated with anlotinib after disease progression in December 2018 and continued to have clinical benefit for nearly 25 months. Unexpectedly, the patient can still benefit from further combination treatment with durvalumab after another disease progression in February 2021. Thus, it may be a potential option to use anlotinib along with immunotherapy after the anlotinib resistance in SCLC, but more clinical data are still needed to confirm it. Moreover, ctDNA dynamic monitoring was performed and reflected the outcome of the process of treatment.https://www.frontiersin.org/articles/10.3389/fonc.2022.956372/fullextensive-stage small cell lung canceranlotinibdurvalumablong survivalNGSbTMB |
| spellingShingle | Huaiyu Wang Xuning Wang Suxin Jiang Jingna Zhu Jie Liu Chuanhong Zhou Yanjun Zhu Yong Han Personalized treatment of extensive stage small cell lung cancer: A case report and literature review Frontiers in Oncology extensive-stage small cell lung cancer anlotinib durvalumab long survival NGS bTMB |
| title | Personalized treatment of extensive stage small cell lung cancer: A case report and literature review |
| title_full | Personalized treatment of extensive stage small cell lung cancer: A case report and literature review |
| title_fullStr | Personalized treatment of extensive stage small cell lung cancer: A case report and literature review |
| title_full_unstemmed | Personalized treatment of extensive stage small cell lung cancer: A case report and literature review |
| title_short | Personalized treatment of extensive stage small cell lung cancer: A case report and literature review |
| title_sort | personalized treatment of extensive stage small cell lung cancer a case report and literature review |
| topic | extensive-stage small cell lung cancer anlotinib durvalumab long survival NGS bTMB |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.956372/full |
| work_keys_str_mv | AT huaiyuwang personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview AT xuningwang personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview AT suxinjiang personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview AT jingnazhu personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview AT jieliu personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview AT chuanhongzhou personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview AT yanjunzhu personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview AT yonghan personalizedtreatmentofextensivestagesmallcelllungcanceracasereportandliteraturereview |